We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
The current RGO market cap is 107.61B. The company's latest EPS is USD 35.8813 and P/E is 29.80.
| Year End December 30 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD ($) | USD ($) | USD ($) | USD ($) | USD ($) | |
| Total Revenue | 7.86B | 8.78B | 16.12B | 12.26B | 13.12B |
| Operating Income | 2.21B | 3.58B | 8.95B | 4.74B | 4.05B |
| Net Income | 2.12B | 3.51B | 8.08B | 4.34B | 3.95B |
| Year End December 30 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD ($) | USD ($) | USD ($) | USD ($) | USD ($) | |
| Total Assets | 14.81B | 17.16B | 25.43B | 29.21B | 33.08B |
| Total Liabilities | 3.72B | 6.14B | 6.67B | 6.55B | 7.11B |
| Total Equity | 11.09B | 11.03B | 18.77B | 22.66B | 25.97B |
| Year End December 30 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD ($) | USD ($) | USD ($) | USD ($) | USD ($) | |
| Operating | 2.43B | 2.62B | 7.08B | 5.01B | 4.59B |
| Investing | -2.03B | -70.6M | -5.38B | -3.78B | -3.19B |
| Financing | -252.1M | -1.97B | -1.01B | -1.01B | -1.79B |
| Market Cap | 107.61B |
| Price to Earnings Ratio | 29.80 |
| Price to Sales Ratio | 8.98 |
| Price to Cash Ratio | 43.15 |
| Price to Book Ratio | 4.54 |
| Dividend Yield | - |
| Shares Outstanding | 110.19M |
| Average Volume (1 week) | 0 |
| Average Volume (1 Month) | 0 |
| 52 Week Change | - |
| 52 Week High | - |
| 52 Week Low | - |
| Spread (Intraday) | 3.2 (0.33%) |
| Company Name | Regeneron Pharmaceuticals Inc |
| Address |
28 liberty street new york, new york 10005 |
| Website | https://www.regeneron.com |
| Industry | health care diversified (H) |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: 1-888-992-3836 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
